Indaptus Therapeutics Inc - Asset Resilience Ratio

Latest as of December 2023: 0.00%

Indaptus Therapeutics Inc (INDP) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$14.92 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2023)

This chart shows how Indaptus Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Indaptus Therapeutics Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Indaptus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INDP market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Indaptus Therapeutics Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Indaptus Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Indaptus Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for Indaptus Therapeutics Inc (2010–2023)

The table below shows the annual Asset Resilience Ratio data for Indaptus Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.00%	$0.00	$14.92 Million	--
2022-12-31	59.88%	$16.81 Million	$28.06 Million	--
2021-12-31	0.00%	$0.00	$40.58 Million	--
2019-12-31	3.62%	$770.00K	$21.28 Million	+1.45pp
2018-12-31	2.17%	$1.33 Million	$61.51 Million	-0.66pp
2017-12-31	2.83%	$1.82 Million	$64.55 Million	-4.66pp
2016-12-31	7.49%	$1.85 Million	$24.72 Million	-11.40pp
2015-12-31	18.90%	$7.04 Million	$37.28 Million	+2.81pp
2014-12-31	16.08%	$2.01 Million	$12.49 Million	-21.59pp
2013-12-31	37.67%	$5.15 Million	$13.68 Million	-1.86pp
2012-12-31	39.53%	$3.07 Million	$7.77 Million	+22.72pp
2011-12-31	16.81%	$1.52 Million	$9.06 Million	-23.81pp
2010-12-31	40.62%	$5.09 Million	$12.54 Million	--

pp = percentage points

About Indaptus Therapeutics Inc

NASDAQ:INDP USA Biotechnology

Market Cap

$2.89 Million

Market Cap Rank

#29515 Global

#5942 in USA

Share Price

$1.29

Change (1 day)

-10.42%

52-Week Range

$1.06 - $8.44

All Time High

$8680.00